CLINICAL-MODELS OF AUTOTRANSPLANTS IN CHRONIC MYELOGENOUS LEUKEMIA

We analysed relapse risk after syngeneic and allogeneic T cell deplete d transplants to predict the outcome after autotransplants in chronic myelogenous leukemia (CML). These data suggest that high dose pre-tran splant conditioning may cure about 50% of the persons in chronic phase and about 10% of those in more advanced phases. The expected relapse rate would be about 50-90%. However, additional relapses might occur f rom infusing leukemia cells with the graft. Different approaches are b eing attempted to eliminate leukemia cells from the graft. It is howev er unlikely that their effect could be demonstrated in clinical trials . Recent analyses in persons relapsing after allogeneic T depleted tra nsplants suggest that reducing the CML cell mass by high dose chemothe rapy may prolong duration of survival.